Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan

被引：0
|
作者：
Bae, Jung-Woo
Han, Ho-Kyun
Lee, Hwan-Joo
Jung, Dong -Won
Kim, Nam-Tae
Lee, Jin-Hee
Jang, Choon-Gon
Choi, Sun-Ok
Kim, Ok-Hee
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [41] Evaluation of losartan (L) as a CYP2C9 probe.
    Pieper, JA
    Johnson, ME
    Allen, TL
    Clarke, M
    Greenwood, R
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P69 - P69
  • [42] The Effect of UGT 1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
    Pavlovic, Dimitrije
    Budic, Ivana
    Stoimenov, Tatjana Jevtovic
    Stokanovic, Dragana
    Marjanovic, Vesna
    Stevic, Marija
    Slavkovic, Milan
    Simic, Dusica
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 13 - 27
  • [43] A mutation in CYP2C9 is responsible for decreased metabolism of losartan
    Spielberg, S
    McCrea, J
    Cribb, A
    Rushmore, T
    Waldman, S
    Bjornsson, T
    Lo, MW
    Goldberg, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : OIII1 - OIII1
  • [44] CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers
    Zhou, Q.
    Ruan, Z. -r.
    Yuan, H.
    Zeng, S.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (11): : 519 - 524
  • [45] Effect of CYP2C9 polymorphism on the pharmacokinetics of candesartan in healthy Korean subjects.
    Lee, Seok-Yong
    Bae, Jung-Woo
    Han, Ho-Kyun
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Jung, Dong-Won
    Lee, Hwan-Joo
    Choi, Sun-Ok
    Kim, Ok-Hee
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 235 - 235
  • [46] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Satoshi Yamaori
    Mika Kushihara
    Kyoko Koeda
    Ikuo Yamamoto
    Kazuhito Watanabe
    Forensic Toxicology, 2013, 31 : 70 - 75
  • [47] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [48] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Sekino, K
    Kubota, T
    Okada, Y
    Yamada, Y
    Yamamoto, K
    Horiuchi, R
    Kimura, K
    Iga, T
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 589 - 592
  • [49] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Kazuishi Sekino
    Takahiro Kubota
    Yuko Okada
    Yasuhiko Yamada
    Koujirou Yamamoto
    Ryuya Horiuchi
    Kenjirou Kimura
    Tatsuji Iga
    European Journal of Clinical Pharmacology, 2003, 59 : 589 - 592
  • [50] The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Eui-Hyun Jung
    Won-Ki Chae
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2018, 41 : 931 - 936
12345